Eukaryotic translation initiation factor eIF4E, the mRNA cap-binding protein, is considered the rate-limiting factor in translation. It plays an important role in cap-dependent translation initiation and recruitment of mRNA to ribosomes. Overexpression of eIF4E has been documented in numerous human cancers and contributes to transformation, tumorigenesis, and progression of cancers. Therefore, eIF4E is an attractive drug target for cancer treatment.